Validation of HAV biomarker 2A for differential diagnostic of hepatitis A infected and vaccinated individuals using multiplex serology.

Bohm, Katrin; Filomena, Angela; Schneiderhan-Marra, Nicole; Krause, Gerard; Sievers, Claudia

dc.contributor.author	Bohm, Katrin
dc.contributor.author	Filomena, Angela
dc.contributor.author	Schneiderhan-Marra, Nicole
dc.contributor.author	Krause, Gerard
dc.contributor.author	Sievers, Claudia
dc.date.accessioned	2017-10-10T13:58:49Z
dc.date.available	2017-10-10T13:58:49Z
dc.date.issued	2017-10-13
dc.identifier.citation	Validation of HAV biomarker 2A for differential diagnostic of hepatitis A infected and vaccinated individuals using multiplex serology. 2017, 35 (43):5883-5889 Vaccine	en
dc.identifier.issn	1873-2518
dc.identifier.pmid	28919226
dc.identifier.doi	10.1016/j.vaccine.2017.08.089
dc.identifier.uri	http://hdl.handle.net/10033/621133
dc.description.abstract	Worldwide about 1.5 million clinical cases of hepatitis A virus (HAV) infections occur every year and increasingly countries are introducing HAV vaccination into the childhood immunization schedule with a single dose instead of the originally licenced two dose regimen. Diagnosis of acute HAV infection is determined serologically by anti-HAV-IgM detection using ELISA. Additionally anti-HAV-IgG can become positive during the early phase of symptoms, but remains detectable after infection and also after vaccination against HAV. Currently no serological marker allows the differentiation of HAV vaccinated individuals and those with a past infection with HAV. Such differentiation would greatly improve evaluation of vaccination campaigns and risk assessment of HAV outbreaks. Here we tested the HAV non-structural protein 2A, important for the capsid assembly, as a biomarker for the differentiation of the immune status in previously infected and vaccinated individuals.
dc.language.iso	en	en
dc.rights.uri	http://creativecommons.org/licenses/by-nc-sa/4.0/	*
dc.title	Validation of HAV biomarker 2A for differential diagnostic of hepatitis A infected and vaccinated individuals using multiplex serology.	en
dc.type	Article	en
dc.contributor.department	Helmholtz-Zentrum für Infektionsforschung GmbH, Inhoffenstr. 7, 38124 Braunschweig, Germany.	en
dc.identifier.journal	Vaccine	en
refterms.dateFOA	2018-06-12T22:47:18Z
html.description.abstract	Worldwide about 1.5 million clinical cases of hepatitis A virus (HAV) infections occur every year and increasingly countries are introducing HAV vaccination into the childhood immunization schedule with a single dose instead of the originally licenced two dose regimen. Diagnosis of acute HAV infection is determined serologically by anti-HAV-IgM detection using ELISA. Additionally anti-HAV-IgG can become positive during the early phase of symptoms, but remains detectable after infection and also after vaccination against HAV. Currently no serological marker allows the differentiation of HAV vaccinated individuals and those with a past infection with HAV. Such differentiation would greatly improve evaluation of vaccination campaigns and risk assessment of HAV outbreaks. Here we tested the HAV non-structural protein 2A, important for the capsid assembly, as a biomarker for the differentiation of the immune status in previously infected and vaccinated individuals.